New quarterly report expected Apr 22, 2026. Report will refresh after results.
E
Elevance Health Inc.
ELV · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Cheap on Earnings, Expensive on Cash: Elevance's Hidden Ledger
The market is pricing Elevance as a beaten-down managed care franchise on the verge of a repricing cycle recovery — what it's underweighting is that the earnings multiple is cheap precisely because cash conversion has broken down, and with net debt at seven times current free cash flow, the equity absorbs all the downside if the 2027 recovery is six months late.
Flowly Score
Apr 16 Close
-22%$315.82
Fair Value
$245.00
33
Weakat $315.82
Business Strength5/10
The BCBS territorial licenses and scale advantages are genuine and durable, but the economic returns those moats used to generate have been compressing in a straight line for five years — a moat that no longer converts structural advantages into rising returns is a moat that's been breached at the margin. Management's serial guidance misses in a data-intensive business further erode confidence that the Carelon vertical integration bet will execute as advertised.
Financial Resilience4/10
A business that used to be a textbook cash machine has watched its free cash flow cut by more than half while net debt sits at nearly seven times current annual cash generation — that ratio leaves almost no cushion if the trough is deeper or longer than management projects. The Altman Z sitting below 3.0 and a Q4 that generated negative free cash flow are not existential signals, but they confirm that financial flexibility has been meaningfully impaired.
Growth & Trajectory3/10
Revenue is growing but earnings are falling, membership is declining across the highest-margin government segments, and the company itself has declared 2026 a trough year with EPS guided sharply lower — this is a business moving backward on every metric that matters while buybacks paper over the severity. The 2027 recovery thesis is plausible given managed care's historical repricing cycles, but it comes from a management team that has earned little credibility forecasting their own near-term trajectory.
Valuation4/10at $291.63
The P/E looks historically cheap and is attracting value-oriented attention, but it's the wrong denominator — cash conversion has deteriorated so sharply that the earnings multiple flatters what you're actually buying, and the neutral DCF scenario lands below the current price without heroic assumptions. This isn't extreme overvaluation, but it's not a screaming margin of safety either; it's a value trap dressed as a value opportunity, contingent entirely on a recovery that hasn't yet begun.
Risk3/10
The risk stack is genuinely elevated: near-seven-times leverage on depressed cash flows, pure undiversified exposure to federal and state healthcare funding decisions, a CMS that has demonstrated willingness to structurally reprice Medicare Advantage, and a political environment where Medicaid cuts are an active policy agenda rather than background noise. The management visibility problem compounds it — when you're repeatedly surprised by cost trends in a business built on predicting cost trends, the guidance you receive about the path forward deserves a steep credibility discount.
Elevance's BCBS territorial licenses remain the most underappreciated franchise asset in American healthcare — a legally protected brand monopoly across fourteen states that no amount of capital can replicate. The problem is that a structural moat and an economic moat are not the same thing, and the former has been slowly severed from the latter. The business still earns money; it earns less on every incremental dollar deployed, and the cash that used to flow freely has slowed to a trickle. The P/E looks historically cheap, but cash conversion is the honest test, and cash conversion has failed it. The Carelon vertical integration strategy is the right long-term instinct — the playbook of owning pharmacy, behavioral health, and care management has worked for rivals who built it earlier and better. But Elevance is attempting this transformation while simultaneously navigating a government program margin crisis, a Medicare Advantage deliberate retrenchment, and Medicaid rates running a full year behind cost reality. Executing a multi-year services buildout while your core insurance economics are under active pressure is the operational equivalent of renovating a house during a flood. The 2027 recovery narrative depends on the repricing cycle working as it historically has — a reasonable assumption, but not a certain one. The single decisive risk is federal Medicaid policy. This is not abstract regulatory risk — it is a specific, live legislative agenda that would directly impair the revenue line of the segment management calls its trough. Medicaid is not just a problem segment; it is the growth-stage bet that justified the premium Elevance commanded three years ago. If federal funding is cut meaningfully before the repricing cycle closes the gap between costs and rates, the spiral deepens sharply — operating leverage works viciously in reverse, and a $23.7 billion debt load amplifies every turn of the screw directly into equity value.